Register for OBR daily

Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PBYI $233.43 174.4000 +295.44%
INO $13.10 1.9600 +17.59%
ONTY $3.29 0.4900 +17.50%
ARIA $5.88 0.7800 +15.29%
TGTX $9.31 1.0550 +12.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GSK $50.04 -3.1800 -5.98%
FPRX $13.53 -0.5800 -4.11%
PPHM $1.57 -0.0550 -3.38%
KPTI $35.03 -1.0400 -2.88%
RNN $0.71 -0.0194 -2.66%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

My Wife's Cancer Holds Lesson for Health Care: David Klein

(Bloomberg Opinion) Dec 23, 2010 - In July 2008, my wife Linde was diagnosed with advanced squamous cell carcinoma of the oral cavity. Her subsequent treatment has led me to view U.S. medical care from a different perspective.
read article 

Firms Fight Move to Obtain Cheap Anti-Blindness Drug Avastin

(The Guardian UK) Jan 2, 2011 - Nice moves towards official appraisal of drug to prevent a cause of blindness, for which makers will not seek a license.
read article 

Roche Buys Biopharma Rising Star in Carmel

(Indianapolis Star) Dec 31, 2010 - A small biopharmaceutical company in Carmel with extensive ties to Eli Lilly and Co. has been purchased by Swiss-headquartered Roche, an international life sciences behemoth.
read article 

Cephalon Names Buchi as CEO After Founder Baldino's Death From Leukemia

(Bloomberg) Dec 23, 2010 - Cephalon Inc.’s J. Kevin Buchi, who had been serving as acting chief executive officer since August, will take over the position following last week’s death of company founder Frank Baldino.
read article 

Vaccine Approved for Anal Cancer Prevention

(Los Angeles Times) Dec 22, 100 - Gardasil, the vaccine that can prevent most cases of cervical cancer in girls, has won the FDA's blessing as a vaccine to prevent anal cancer, a rare but growing diagnosis in the United States.
read article (free registration required) 

Congress Passes Legislation to Maintain Current Funding Level for NIH Through March 2011

(ASH) Dec 22, 2010 - Prior to adjourning for the year, Congress reached agreement on and passed a spending bill that will maintain current funding levels for the National Institutes of Health (NIH) and most other federal programs through March 4, 2011. The bill (HR 3082) passed the Senate by a vote of 79-16, and was cleared by the House by a vote of 193-165. President Obama has said he will sign the measure into law.
read press release 

NICE Gives Green Light to Leukemia Drug in Draft Guidance

(NICE) Dec 23, 2010 - Issued today (23 December), the draft guidance recommends the use of bendamustine (Levact, Napp Pharmaceuticals) as a first-line treatment for patients with chronic lymphocytic leukemia (Binet stage B or C) for whom a type of intensive treatment called fludarabine combination chemotherapy is not appropriate.
read press release 

Stopgap Funding Bill Omits CMS Funding Increase Needed to Implement Health Reform

(ASH) Dec 22, 2010 - Prior to adjourning for the year, Congress reached agreement on and passed a spending bill that will maintain current funding levels for the National Institutes of Health (NIH) and most other federal programs through March 4, 2011.
read press release 

Opinion: The FDA Is Evading the Law

(Wall Street Journal) Dec 23, 2010 - Europeans are approving important new drugs more rapidly than we are.
read article (paid subscription required) 

Marrow Donors Angry Over Charity’s High Bills

(Boston Globe) Dec 23, 2010 - Joanne Miller, who lost her own husband to cancer, was thrilled when she saw recruiters for the Caitlin Raymond International Registry signing up people at the Topsfield Fair for bone marrow testing.
read article (free registration required) 

Gardasil Approved to Prevent Anal Cancer

(FDA) Dec 22, 2010 - The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.
read press release 

McKesson: US Oncology Acquisition on Hold

(Bloomberg) Dec 22, 2010 - Medical supplies distributor McKesson Corp. said Wednesday that an interim court order has stalled its $560 million cash acquisition of US Oncology Holdings Inc.
read article 

NCI Announces Plans to Reinvigorate Clinical Trials

(NCI) Dec 23, 2010 - The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies.
read press release 

Gene Mutation Suggests New Treatment Target for Specific Lymphoma

(U.S. News & World Report) Dec 22, 2010 - Researchers have identified a gene mutation that may offer a target for new treatments for a type of lymphoma. The team found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as large B cell lymphoma.
read article 

Many Cancer Cells Found to Have an 'Eat Me' Signal in Study

(Stanford University School of Medicine) Dec 22, 2010 - Researchers at the Stanford University School of Medicine have discovered that many cancer cells carry the seeds of their own destruction — a protein on the cell surface that signals circulating immune cells to engulf and digest them.
read press release 

Most Common Adult Brain Cancer Linked to Gene Deletion, Doctors Say

(Stanford University School of Medicine) Dec 22, 2010 - A study published online Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer. This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient’s survival prospects.
read press release 

Researchers from Mount Sinai School of Medicine Make Major Breakthrough in Melanoma Research

(Mount Sinai School of Medicine) Dec 22, 2010 - In a breakthrough that could lead to new treatments for patients with malignant melanoma, researchers from Mount Sinai School of Medicine have discovered that a particular protein suppresses the progression of melanoma through regulation of an oncogene, or gene responsible for cancer growth.
read press release 

CU Cancer Center Touts New Lung Treatments

(The Aurora Sentinel) Dec 22, 2010 - A new cocktail of drug treatments shows promise in treating a specific kind of lung cancer, according to researchers at the University of Colorado Cancer Center. UCCC researchers say data from new trials show that a combination of two drugs was more effective in treating non-small cell lung cancer, or NSCLC. The combination of entinostat and erlotinib targeted E-cadherin, a specific cancer marker for NSCLC.
read article 

Penn Researchers Identify Potential Target for Breast Cancer Therapy

(Penn Medicine) Dec 22, 2010 - Now, Marcelo G. Kazanietz, PhD, professor of Pharmacology at the University of Pennsylvania School of Medicine and colleagues, report that a protein called P-Rex1 is crucial for signal transmission from ErbB receptors. What’s more, they found that P-Rex1 is overexpressed in nearly 60 percent of breast cancer samples tested and patients whose tumors express P-Rex1 were more likely to develop metastasis, compared with those whose tumors did not express P-Rex1.
read press release 

High Red Blood Folate Levels Linked to Silenced Tumor-Suppressors

(MD Anderson) Dec 20, 2010 - People with higher levels of folate in their red blood cells were more likely to have two cancer-preventing genes shut down by methylation -- a chemical off switch for genes, researchers report this week in the December issue of Cancer Prevention Research.
read article 

Some Cancer Drugs May Block Cellular “Cross Talk,” But Not Kill Cancer Cells

(UCCC) Dec 22, 2010 - A class of drugs thought to kill cancer cells may in fact block “cross talk” between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread—a discovery that could significantly alter the way cancer drugs are evaluated in the future.
read press release 

Myrexis Initiates Comparative-Arm Phase 2 Study of Azixa(TM) for the Front-Line Treatment of Glioblastoma Multiforme

(Yahoo! Finance) Dec 22, 2010 - Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).
read article 

Phase 2 Trial of Belinostat, a Novel HDAC Inhibitor, in the Treatment of Carcinoma of Unknown Primary (CUP) Meets Enrollment Target

(SmartBrief) Dec 23, 2010 - Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP).
read article 

Doctor Frustrated by Delay: Cancer Institute 'Not Fulfilling Their Commitment'

(Knoxville Business News) Dec 22, 2010 - All Dr. Alan Solomon wants for Christmas is an antibody. After 15 years spent seeking a cure for a rare disease known as amyloidosis, the University of Tennessee physician and medical scientist has seen his work stalled just short of reaching what he believes could be a promising solution.
read article 

Multiple Myeloma Research Consortium (MMRC) Welcomes Baylor Charles A. Sammons Cancer Center at Dallas, Satah Cannon Research Institute, and Virginia Cancer Specialists as Member Institutions

(MMRC) Dec 22, 2010 - The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA).
read press release